News | Heart Valve Technology | November 02, 2018

Valve Replacement Volume Key to Successful Patient Outcomes

New study finds patient outcomes are best at healthcare facilities that perform high volumes of both surgical and transcatheter aortic valve replacements

Valve Replacement Volume Key to Successful Patient Outcomes

November 2, 2018 — Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to adopt a newer, less invasive technique, according to a new study, published Oct. 31 in JAMA Cardiology from Weill Cornell Medicine.1 When hospitals have a high caseload of both, they are likely to achieve the best patient outcomes for those who undergo the newer procedure.

“You can imagine that hospitals known for valve care are more likely to attract valve patients and adopt TAVR [transcatheter aortic valve replacement] more quickly,” said senior author Art Sedrakyan, M.D., Ph.D., a professor of healthcare policy and research at Weill Cornell Medicine. “And it’s likely that the more experience the hospitals have in performing valve surgery, the better patient outcomes are.”

In the study, the investigators sought to examine the relationship between the number of times hospitals perform the established procedure, called surgical aortic valve replacement (SAVR), and patient outcomes from the less invasive TAVR. TAVR has gained popularity in recent years, as it allows surgeons to deliver a valve replacement using only a catheter. TAVR was first approved in 2011 for high-risk patients who were considered inoperable.

Recently, the Centers for Medicare & Medicaid Services (CMS) set criteria to promote high-quality implementation of TAVR, including the requirement that hospitals perform at least 50 SAVR procedures a year prior to beginning TAVR procedures. Due to scrutiny over the requirements, a Medicare Evidence Development & Coverage Advisory Committee panel took place in July to discuss the issue. While some attendees argued for lowering the requirements, as they are difficult to reach in less populated areas, others posited that hospitals with high SAVR numbers would have lower complication rates for TAVR.

To discern that relationship, the Weill Cornell Medicine team, led by Sedrakyan, analyzed more than 60,000 TAVR procedures performed at hospitals between 2011 and 2015. They ultimately found that high volumes of both procedures was associated with the best outcomes for TAVR.

“It’s important that we evaluate TAVR and SAVR in a conjoined way. That’s what makes this study novel – previous studies have not assessed the effect of SAVR volume,” said first author Jialin Mao, M.D., an instructor in healthcare policy and research at Weill Cornell Medicine.

When researchers looked at patient mortality rates 30 days and then one year after undergoing TAVR, they found that patients treated at hospitals with high SAVR volume and high TAVR volume had the lowest mortality. “Patients need to know that getting care at institutions with the highest volume of aortic valve interventional care is most beneficial to them,” Sedrakyan said.

The findings suggest that federal requirements determining hospital eligibility for Medicare and Medicaid reimbursement for TAVR procedures are appropriate and could even be more restrictive.

“Current restrictions need to be maintained and made even stronger,” Sedrakyan said. “We don’t believe the time is right for widespread access to these technologies at the expense of patient safety.”

For more information: www.jamanetwork.com/journals/jamacardiology

Reference

1. Mao J., Redberg R.F., Carroll J.D., et al. Association Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes. JAMA Cardiology, published online Oct. 31, 2018. doi:10.1001/jamacardio.2018.3562

Related TAVR Content

Higher Volume of TAVR Boosts Key In-Hospital Outcomes

VIDEO: Impact of TAVR Procedural Volume on Patient Outcomes at ACC.16


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now